Tuberous sclerosis-2 tumor suppressor modulates ERK and B-Raf activity in transformed renal epithelial cells

American Journal of Physiology - Renal Physiology

Volumn 286, Issue 2 55-2, 2004, Pages

  Yoon, Hae Seong ^a   Ramachandiran, Sampath ^a   Chacko, Mary Anne S ^a   Monks, Terrence J ^a   Lau, Serrine S ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cell cycle extracellular signal regulated kinase; Quinol thioether reactive oxygen species

Indexed keywords

COMPLEMENTARY DNA; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; TUBERIN;

ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; DNA SYNTHESIS INHIBITION; ENZYME REGULATION; GENE; HETEROZYGOSITY LOSS; KIDNEY TUBULE CELL; KIDNEY TUMOR; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TSC 2 GENE; TUMOR SUPPRESSOR GENE;

EID: 0942301309     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00234.2003     Document Type: Article

References (41)

1. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, Cheadle JP, Halley DJ, Sampson JR, Wienecke R, and DeClue JE. The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19: 6306-6316, 2000.
2. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, and Rapp UR. The ins and outs of Raf kinases. Trends Biochem Sci 19: 474-480, 1994.
3. Fukuda T, Kobayashi T, Yasui H, Tsutsumi M, Konishi Y, and Hino O. Distribution of Tsc2 protein in various normal rat tissues and renal tumours of Tsc2 mutant (Ekcr) rat detected by immunohistochemistry. Virchows Arch 434: 341-350. 1999.
4. Hara I, Miyake H, Hara S, Arakawa S, and Kamidono S. Sodium butyrate induces apoptosis in human renal cell carcinoma cells and synergistically enhances their sensitivity to anti-Fas-mediated cytotoxicity. Int J Oncol 17: 1213-1218, 2000.
5. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, and Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18: 913-822, 1999.
6. Huang C, Ma WY, Young MR, Colburn N, and Dong Z. Shortage of mitogen-activated protein kinase is responsible for resistance to AP-1 transactivation and transformation in mouse JB6 cells. Proc Natl Acad Sci USA 95: 156-161, 1998.
7. Inoki K, Li Y, Zhu T, Wu J, and Guan KL. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648-657, 2002.
8. Ito N and Rubin GM. Gigas, a Drosophila homolog of tuberous sclerosis gene product-2, regulates the cell cycle. Cell 96: 529-539, 1999.
9. Jin F, Wienecke R, Xiao GH, Maize JC Jr, DeClue JE, and Yeung RS. Suppression of tumorigenicity by the wild-type tuberous sclerosis 2 (Tsc2) gene and its C-terminal region. Proc Natl Acad Sci USA 93: 9154-9159, 1996.
10. Kobayashi T, Urakami S, Cheadle JP, Aspinwall R, Harris P, Sampson JR, and Hino O. Identification of a leader exon and a core promoter for the rat tuberous sclerosis 2 (Tsc2) gene and structural comparison with the human homolog. Mamm Genome 8: 554-558, 1997.
11. Lau SS, Monks TJ, Everitt JI, Kleymenova E, and Walker CL. Carcinogenicity of a nephrotoxic metabolite of the "nongenotoxic" carcinogen hydroquinone. Chem Res Toxicol 14: 25-33, 2001.
12. 1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271: 20608-20616, 1996.
13. Liao DZ, Hou X, Bai S, Li SA, and Li JJ. Unusual deregulation of cell cycle components in early and frank estrogen-induced renal neoplasias in the Syrian hamster. Carcinogenesis 21: 2167-2173, 2000.
14. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, Vande Woude GF, and Ahn NG. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970, 1994.
15. Marais R, Light Y, Paterson HF, Mason CS, and Marshall CJ. Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272: 4378-4383, 1997.
16. Marshall CJ. Cell signalling. Raf gets it together. Nature 383: 127-128, 1996.
17. Marshall CJ. MAP kinase kinase kinase, MAP kinase kinase and MAP kinase. Curr Opin Genet Dev 4: 82-89, 1994.
18. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179-185, 1995.
19. Morrison DK and Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol 9: 174-179, 1997.
20. Nassar N, Horn G, Herrmann C, Scherer A, McCormick F, and Wittinghofer A. The 2.2 A crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with Rap1A and a GTP analogue. Nature 375: 554-560, 1995.
21. Oka H, Chatani Y, Hoshino R, Ogawa O, Kakehi Y, Terachi T, Okada Y, Kawaichi M, Kohno M, and Yoshida O. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res 55: 4182-4187, 1995.
22. Okazaki K and Sagata N. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. Oncogene 10: 1149-1157, 1995.
23. Orimoto K, Tsuchiya H, Kobayashi T, Matsuda T, and Hino O. Suppression of the neoplastic phenotype by replacement of the Tsc2 gene in Eker rat renal carcinoma cells. Biochem Biophys Res Commun 219: 70-75, 1996.
24. Potter CJ, Huang H, and Xu T. Drosophila Tsc1 functions with Tsc2 to antagonize insulin signaling in regulating cell growth, cell proliferation, and organ size. Cell 105: 357-368, 2001.
25. Soucek T, Pusch O, Wienecke R, DeClue JE, and Hengstschlager M. Role of the tuberous sclerosis gene-2 product in cell cycle control. Loss of the tuberous sclerosis gene-2 induces quiescent cells to enter S phase. J Biol Chem 272: 29301-29308, 1997.
26. Soucek T, Yeung RS, and Hengstschlager M. Inactivation of the cyclin-dependent kinase inhibitor p27 upon loss of the tuberous sclerosis complex gene-2. Proc Natl Acad Sci USA 95: 15653-15658, 1998.
27. Tapon N, Ito N, Dickson BJ, Treisman JE, and Hariharan IK. The Drosophila tuberous sclerosis complex gene homologs restrict cell growth and cell proliferation. Cell 105: 345-355, 2001.
28. Tee AR, Fingar DC, Manning BD, Kwiatkowski DJ, Cantley LC, and Blenis J. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci USA 99: 13571-13576, 2002.
29. Troppmair J, Bruder JT, App H, Cai H, Liptak L, Szeberenyi J, Cooper GM, and Rapp UR. Ras controls coupling of growth factor receptors and protein kinase C in the membrane to Raf-1 and B-Ra1 protein serine kinases in the cytosol. Oncogene 7: 1867-1873, 1992.
30. Tsuchiya H, Orimoto K, Kobayashi K, and Hino O. Presence of potent transcriptional activation domains in the predisposing tuberous sclerosis (Tsc2) gene product of the Eker rat model. Cancer Res 56: 429-433, 1996.
31. Valencia A, Chardin P, Wittinghofer A, and Sander C. The ras protein family: evolutionary tree and role of conserved amino acids. Biochemistry 30: 4637-4648, 1991.
32. Vossler MR, Yao H, York RD, Pan MG, Rim CS, and Stork PJ. cAMP activates MAP kinase and Elk-1 through a B-Raf- and Rap1-dependent pathway. Cell 89: 73-82, 1997.
33. Walker C. Molecular genetics of renal carcinogenesis. Toxicol Pathol 26: 113-120, 1998.
34. Wessler S, Rapp UR, Wiedenmann B, Meyer TF, Schoneberg T, Hocker M, and Naumann M. B-Raf/Rap1 signaling, but not c-Raf-1/Ras, induces the histidine decarboxylase promoter in Helicobacter pylori infection. FASEB J 16: 417-419, 2002.
35. Wienecke R, Konig A, and DeClue JE. Identification of tuberin, the tuberous sclerosis-2 product. Tuberin possesses specific Rap1GAP activity. J Biol Chem 270: 16409-16414, 1995.
36. Wienecke R, Maize JC Jr, Reed JA, de Gunzburg J, Yeung RS, and DeClue JE. Expression of the TSC2 product tuberin and its target Rap1 in normal human tissues. Am J Pathol 150: 43-50, 1997.
37. Wienecke R, Maize JC Jr, Shoarinejad F, Vass WC, Reed J, Bonifacino JS, Resau JH, de Gunzburg J, Yeung RS, and DeClue JE. Colocalization of the TSC2 product tuberin with its target Rap1 in the Golgi apparatus. Oncogene 13: 913-923, 1996.
38. Xiao GH, Shoarinejad F, Jin F, Golemis EA, and Yeung RS. The tuberous sclerosis 2 gene product, tuberin, functions as a Rab5 GTPase activating protein (GAP) in modulating endocytosis. J Biol Chem 272: 6097-6100, 1997.
39. Yoon HS, Monks TJ, Everitt JI, Walker CL, and Lau SS. Cell proliferation is insufficient, but loss of tuberin is necessary, for chemically induced nephrocarcinogenicity. Am J Physiol Renal Physiol 283: F262-F270, 2002.
40. Yoon HS, Monks TJ, Walker CL, and Lau SS. Transformation of kidney epithelial cells by a quinol thioether via inactivation of the tuberous sclerosis-2 tumor suppressor gene. Mol Carcinog 31: 37-45, 2001.
41. York RD, Yao H, Dillon T, Ellig CL, Eckert SP, McCleskey EW, and Stork PJ. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392: 622-626, 1998.